Advanced search×

Risperidone long-acting injection: a prospective 3-year analysis of its use in clinical practice.

David M Taylor, Catrin Fischetti, Anna Sparshatt, Arwel Thomas, Delia Bishara, and Victoria Cornelius

J Clin Psychiatry 70(2):196-200 (2009) PMID 19026261

To evaluate outcomes of clinical use of risperidone long-acting injection (RLAI) and determine factors predicting continuation with treatment.

DOI: 10.4088/JCP.08m04427
Version: za2963e q8zab q8zbf q8zcc q8zdb q8ze4 q8zf2 q8zg0

Similar articles you may find interesting…

  1. Risperidone and lamotrigine: no evidence of a drug interaction.
    Ingrid Castberg and Olav Spigset

    J Clin Psychiatry 67(7):1159 (2006) PMID 16889467

  2. Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study.
    Roberto Cavallaro, Federica Cocchi, ... Enrico Smeraldi

    J Clin Psychiatry 65(2):187-90 (2004) PMID 15003071

    Results suggest that low-dose cabergoline treatment of risperidone-induced hyperprolactinemia may be safe and clinically effective in a relevant number of patients....
  3. [Risperidone use in child and adolescent psychiatric patients].
    Claire C Chevreuil, Jean-Michel JM Reymann, ... Danièle D Bentué-Ferrer

    Therapie 63(5):359-75 (2008) PMID 19154706

    We have done a review of the literature on the effectiveness and the cautions for prescription of risperidone, a second generation antipsychotic drug. Risperidone has proved helpful in treating children and adolescents with autism spectrum, conduct and bipolar disorders, Tourette's syndrome, and sch...